达拉非尼联合曲美替尼治疗3期随机试验中与临床结局相关因素的3年汇总分析
该研究回顾性汇总了COMBI-d和COMBI-v两项3期随机试验中接受达拉非尼联合曲美替尼(D+T)治疗的BRAF突变黑色素瘤患者3年标志性数据,共563例,3年无进展生存(PFS)率为23%,3年总生存(OS)率为44%。基线乳酸脱氢酶(LDH)水平和转移器官部位数仍与PFS和OS强相关/具有预测性,基线病灶直径总和(SLD)也被确定为进展的预测因素。
要点
- 在D+T治疗的BRAF突变黑色素瘤患者中,3年PFS率为23%,3年OS率为44%。
- 基线LDH水平和转移器官部位数是PFS和OS的强相关/预测因素。
- 基线SLD被确定为进展的预测因素;最有利预后组(LDH正常、SLD<66 mm、<3个器官部位,n=183/563)3年PFS率为42%。
核心结论
- 使用目前最大的BRAF/MEK抑制剂联合治疗黑色素瘤3期数据集,结果表明在接受D+T的BRAF突变黑色素瘤患者亚组中,可持续≥3年的持久缓解是可能的。
- 尽管最佳预测模型随随访延长而演变,但预测联合治疗临床结局的因素与先前分析保持一致。
研究设计与样本
- 回顾性汇总了3期试验COMBI-d(NCT01584648)和COMBI-v(NCT01597908)中接受D+T治疗患者的3年标志性数据。
- 采用单因素和多因素分析评估预定义基线因素的预后价值,回归树分析确定变量间的层级和交互作用。
- 共纳入563例患者。
主要发现
- 长期汇总结局与单项试验结果一致:N=563,3年PFS率为23%,3年OS率为44%。
- 基线LDH水平和器官部位数仍与PFS和OS强相关和/或具有预测性。
- 基线SLD被确定为进展的预测因素。
- 在最有利预后组(LDH正常、SLD<66 mm、<3个器官部位;n=183/563[33%])中,3年PFS率为42%。
- 基线器官部位数还可预测PFS≥6个月患者的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Understanding predictors of long-term benefit with currently available melanoma therapies is the key for optimising individualised treatments. A prior pooled analysis of dabrafenib plus trametinib (D + T)-randomised trials (median follow-up, 20.0 months) identified baseline lactate dehydrogenase (LDH) and number of organ sites with metastasis as predictive factors for progression-free (PFS) and overall (OS) survival. However, longer-term follow-up analyses are needed to confirm which patients treated with D + T can achieve maximum benefit. METHODS: Three-year landmark data were retrospectively pooled for D + T patients in phase 3 trials (COMBI-d [NCT01584648]; COMBI-v [NCT01597908]). Univariate and multivariate analyses assessed prognostic values of predefined baseline factors; regression tree analysis determined hierarchy and interactions between variables. RESULTS: Long-term pooled outcomes were consistent with individual trial results (N = 563; 3-year PFS, 23%; 3-year OS, 44%). Baseline LDH level and number of organ sites remained strongly associated with and/or predictive of PFS and OS. In addition, baseline sum of lesion diameters (SLD) was identified as a predictor for progression. In the most favourable prognostic group (normal LDH, SLD <66 mm, <3 organ sites; n = 183/563 [33%]), 3-year PFS was 42%. Baseline number of organ sites was also predictive of outcomes in patients with PFS ≥ 6 months. CONCLUSION: Using the largest phase 3 data set available for BRAF/MEK inhibitor combination therapy in melanoma, these results demonstrate that durable responses lasting ≥3 years are possible in subsets of patients with BRAF-mutant melanoma receiving D + T. Although the best predictive model evolved with longer follow-up, factors predicting clinical outcomes with the combination remained consistent with previous analyses.
引用
- Schadendorf D, Long GV, Stroiakovski D, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017. PMID: 28648698. doi:10.1016/j.ejca.2017.05.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。